Xeris Biopharma Holdings (XERS) Assets (2020 - 2026)
Xeris Biopharma Holdings' (XERS) quarterly Assets came in at $392.0 million in Q1 2026, up 24.27% YoY from $315.5 million in Q1 2025, and up 2.21% on a QoQ basis from $383.5 million in Q4 2025.
Xeris Biopharma Holdings (XERS) Assets (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings (XERS) has 7 years of Assets data on file, last reported at $392.0 million in Q1 2026.
- Quarterly Assets rose 24.27% year-over-year to $392.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $392.0 million (up 24.27% YoY) and the FY2025 annual result came in at $383.5 million, up 18.72% from the prior year.
- Assets rose to $392.0 million in Q1 2026, from $383.5 million in the prior quarter.
- In the past five years, Assets ranged from a high of $392.0 million in Q1 2026 to a low of $303.0 million in Q3 2022.
- A 5-year average of $336.0 million and a median of $328.8 million in 2023 frame the typical range for Assets.
- Annual changes were most pronounced in 2022 — Assets soared 130.85% — and 2023, when it declined 6.36%.
- Tracing XERS's Assets over 5 years: stood at $344.5 million in 2022, then decreased by 6.36% to $322.6 million in 2023, then climbed by 0.14% to $323.1 million in 2024, then climbed by 18.72% to $383.5 million in 2025, then grew by 2.21% to $392.0 million in 2026.
- The last three Assets figures came in at $392.0 million (Q1 2026), $383.5 million (Q4 2025), and $370.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 43.71 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 39.86 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 15.08 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 98.27 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 7.22 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 35.04 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 5.36 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 13.56 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 6.18 Bn |
| 10 | Xeris Biopharma Holdings | 1.48 Bn | 1.36 Bn | 79.59 Mn | 411.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 411.91 Mn |
| Mar 31, 2026 | 392.01 Mn |
| Dec 31, 2025 | 383.53 Mn |
| Sep 30, 2025 | 370.19 Mn |
| Jun 30, 2025 | 334.69 Mn |
| Mar 31, 2025 | 315.45 Mn |
| Dec 31, 2024 | 323.06 Mn |
| Sep 30, 2024 | 321.10 Mn |
| Jun 30, 2024 | 331.73 Mn |
| Mar 31, 2024 | 336.62 Mn |
| Dec 31, 2023 | 322.60 Mn |
| Sep 30, 2023 | 327.78 Mn |
| Jun 30, 2023 | 328.78 Mn |
| Mar 31, 2023 | 321.36 Mn |
| Dec 31, 2022 | 344.52 Mn |
| Sep 30, 2022 | 303.02 Mn |
| Jun 30, 2022 | 318.62 Mn |
| Mar 31, 2022 | 337.62 Mn |
| Dec 31, 2021 | 304.36 Mn |
| Sep 30, 2021 | 131.26 Mn |